
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC's KIMMTRAK has achieved a strong market presence, beating quarterly sales estimates in 12 out of 14 quarters since its launch, indicating consistent commercial success in treating unresectable or metastatic uveal melanoma. The company is expanding its pipeline with multiple candidates targeting various therapeutic areas, including the promising TEBE-AM which could enhance the product's commercial opportunities beyond its current indications, potentially leading to peak annual revenues in the range of $500 million. Additionally, the validation of its PRAME franchise and continuous progress in clinical trials further emphasize the company's robust growth trajectory and strong foundation for future revenue expansion.
Bears say
Immunocore Holdings PLC's stock outlook is negatively impacted by underwhelming data from recent clinical trials, particularly in cutaneous melanoma and ovarian cancer, revealing low objective response rates (11% and 6% respectively). The company faces increased competition from emerging therapies, notably IDYA's darovasertib, which poses a threat to Kimmtrak's market share in the HLA-A2+ mUM space, likely affecting its peak market potential. Additionally, Immunocore's pipeline presents high uncertainty due to regulatory and commercial risks, compounded by visibility issues regarding the success of clinical trials for oncology and autoimmune disease programs.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares